Wilson Sonsini Goodrich & Rosati advised Neurona Therapeutics on the transaction. Neurona Therapeutics announced it closed a $120 million financing co-led by Viking Global Investors and Cormorant...
Neurona Therapeutics’ $120 Million Financing
Alector’s $75 Million Common Stock Offering
Wilson Sonsini Goodrich & Rosati represented Alector in the offering, and Davis Polk & Wardwell represented the sole book-running manager and underwriter, Cantor Fitzgerald & Co....
ALX Oncology’s $63 Million Common Stock Offering
Wilson Sonsini Goodrich & Rosati advised ALX Oncology Holdings Inc. on the offering, and Cooley advised the underwriters. ALX Oncology Holdings Inc. (Nasdaq:ALXO) announced the pricing...
Avalyn Pharma’s $175 Million Series C Financing Round
Wilson Sonsini Goodrich & Rosati advised Novo Holdings A/S and Vida Ventures on the transaction. Avalyn Pharma Inc. announced the closing of an oversubscribed $175 million...
Cyclo Therapeutics’ Acquisition of Applied Molecular Transport
Fox Rothschild LLP is acting as legal advisor to Cyclo Therapeutics and Wilson Sonsini Goodrich & Rosati, P.C. is acting as legal advisor to Applied Molecular...
Pyxis Oncology’s Acquisition of Apexigen
Sidley Austin LLP advised Pyxis Oncology, Inc. on the transaction, while Wilson Sonsini advised Apexigen on the transaction. Pyxis Oncology, Inc., a clinical-stage company, and Apexigen,...
Switch’s $52 Million Financing
Wilson Sonsini Goodrich & Rosati advised Switch Therapeutics on the transaction and launch. Switch Therapeutics, a preclinical stage biotechnology company pioneering a new way to use...
Cajal Neuroscience’s $96 Million Series A Financing
Wilson Sonsini Goodrich & Rosati advised Cajal Neuroscience on the deal. Cajal Neuroscience Inc., a biotechnology company integrating human genetics, functional genomics, and advanced microscopy to...
Novartis’ Acquisition of Kedalion Therapeutics
Wilson Sonsini advised Kedalion Therapeutics on the deal. Novartis announced that it acquired Kedalion Therapeutics and its AcuStream technology, an innovative device that may have the...
ReCode Therapeutics’ $120 Million Series B Financing
Wilson Sonsini Goodrich & Rosati represented ReCode Therapeutics in the transaction. ReCode Therapeutics, a genetic medicines company using superior delivery to power the next wave of...
Mirvie’s $60 Million Series B Funding Round
Wilson Sonsini Goodrich & Rosati represented Mirvie on the deal. Mirvie, a pioneer in predicting unexpected pregnancy complications, announced it has raised $60 million in a...
Apexigen’s Business Combination Agreement with Brookline Capital Acquisition Corp.
Wilson Sonsini advised Apexigen on the deal. Apexigen, Inc., a clinical-stage biopharmaceutical company focused on discovering and developing a new generation of antibody therapeutics for oncology,...